1秒率正常的肺功能受损人群现状、挑战及应对策略

doi:10.12114/j.issn.1007-9572.2025.0220

中国全科医学 ›› 2026, Vol. 29 ›› Issue (30): 4366-4371.DOI: 10.12114/j.issn.1007-9572.2025.0220

所属专题：呼吸疾病文章合辑

1秒率正常的肺功能受损人群现状、挑战及应对策略

赵家义¹^,²^,³, 樊剑³, 于德华²^,⁴^,⁵^,^*()

1．200331　上海市，同济大学医学院
2．200090　上海市，同济大学附属杨浦医院全科医学科
3．200081　上海市，上海四一一医院全科医学科
4．200090　上海市全科医学与社区卫生发展研究中心
5．200090　上海市，同济大学医学院全科医学研究中心

收稿日期:2024-10-15 修回日期:2025-12-12 出版日期:2026-10-20 发布日期:2026-09-02
通讯作者: 于德华
作者贡献：
赵家义负责文章的构思与设计、研究资料的收集与整理、论文撰写；樊剑负责资料的收集与整理；于德华负责文章的质量控制及审校，对文章整体负责。
基金资助:
上海市虹口区卫生健康委员会医学科研课题计划资助(虹卫2403-18)

The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry

ZHAO Jiayi¹^,²^,³, FAN Jian³, YU Dehua²^,⁴^,⁵^,^*()

1. School of Medicine, Tongji University, Shanghai 200331, China
2. Department of General Practice, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, China
3. Department of General Practice, Shanghai 411 Hospital, Shanghai 200081, China
4. Shanghai General Practice and Community Health Development Research Center, Shanghai 200090, China
5. General Practice Research Center, School of Medicine, Tongji University, Shanghai 200090, China

Received:2024-10-15 Revised:2025-12-12 Published:2026-10-20 Online:2026-09-02
Contact: YU Dehua

摘要/Abstract

摘要： 1秒率正常的肺功能受损（PRISm）人群是发生慢性阻塞性肺疾病的高危人群，具有不同的临床特征和发展轨迹，与多种全身性合并疾病和不良预后密切相关，目前国内外对其研究仍处于探索阶段。由于对PRISm的认识还不够充分，如缺乏统一标准的临床分型、影像学评估、精准诊断和防治策略等原因，易被忽视或与其他常见呼吸系统和合并疾病相混淆，导致许多患者错过早期干预的机会。因此，全科医生不仅要关注患者是否为PRISm，还要充分关注其临床异质性、与合并疾病的机制关系、影像学早期特征及潜在检测靶点，更要关注PRISm人群的社区筛查和合并疾病的管理。本文对PRISm的现状、挑战及应对策略进行综述。

关键词: 肺疾病，慢性阻塞性, 1秒率正常的肺功能受损, 筛查, 综述

Abstract:

The preserved ratio impaired spirometry (PRISm) population is a high-risk group for chronic obstructive pulmonary disease, with different clinical characteristics and development trajectories, closely related to various systemic comorbidities and poor prognosis. Currently, researches on PRISm are still in the exploratory stage both domestically and internationally. Due to insufficient understanding of PRISm, such as the lack of standardized clinical classification, imaging evaluation, accurate diagnosis, and prevention and treatment strategies, it is easily overlooked or confused with other common respiratory and comorbidities, resulting in many patients missing the opportunity for early intervention. General practitioners should not only pay attention to the patients with PRISm, but also fully consider their clinical heterogeneity, mechanism relationship with comorbidities, early imaging features, and potential detection targets. They should also focus on community screening of PRISm population and management of comorbidities. This article provides an overview of the current status, challenges, and response strategies of PRISm.

Key words: Pulmonary disease, chronic obstructive, Preserved ratio impaired spirometry, Screening, Review

中图分类号:

R 563.9

赵家义,樊剑,于德华. 1秒率正常的肺功能受损人群现状、挑战及应对策略[J]. 中国全科医学, 2026, 29(30): 4366-4371. DOI: 10.12114/j.issn.1007-9572.2025.0220.
ZHAO Jiayi,FAN Jian,YU Dehua. The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry[J]. Chinese General Practice, 2026, 29(30): 4366-4371. DOI: 10.12114/j.issn.1007-9572.2025.0220.

参考文献 56

[1]	Agustí A, Celli B R, Criner G J, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary[J]. European Respiratory Journal, 2023, 61(4): 2300239. DOI: 10.1183/13993003.00239-2023.
[2]	Wan E S, Castaldi P J, Cho M H, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene[J]. Respir Res, 2014, 15(1): 89. DOI: 10.1186/s12931-014-0089-y.
[3]	Klein O L, Kalhan R, Williams M V, et al. Lung spirometry parameters and diffusion capacity are decreased in patients with type 2 diabetes[J]. Diabet Med, 2012, 29(2): 212-219. DOI: 10.1111/j.1464-5491.2011.03394.x.
[4]	Van Westing A C, Ochoa-Rosales C, Van Der Burgh A C, et al. Association of habitual coffee consumption and kidney function: a prospective analysis in the Rotterdam Study[J]. Clin Nutr, 2023, 42(2): 83-92. DOI: 10.1016/j.clnu.2022.11.017.
[5]	Guerra S, Sherrill D L, Venker C, et al. Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study[J]. Thorax, 2010, 65(6): 499-504. DOI: 10.1136/thx.2009.126052.
[6]	Higbee D H, Granell R, Davey Smith G, et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis[J]. Lancet Respir Med, 2022, 10(2): 149-157. DOI: 10.1016/S2213-2600(21)00369-6.
[7]	Kim J, Lee C H, Lee H Y, et al. Association between comorbidities and preserved ratio impaired spirometry: using the Korean national health and nutrition examination survey Ⅳ-Ⅵ[J]. Respiration, 2022, 101(1): 25-33. DOI: 10.1159/000517599.
[8]	Wan E S, Balte P, Schwartz J E, et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults[J]. JAMA, 2021, 326(22): 2287-2298. DOI: 10.1001/jama.2021.20939.
[9]	Washio Y, Sakata S, Fukuyama S, et al. Risks of mortality and airflow limitation in Japanese individuals with preserved ratio impaired spirometry[J]. Am J Respir Crit Care Med, 2022, 206(5): 563-572. DOI: 10.1164/rccm.202110-2302oc.
[10]	Perez-Padilla R, Montes De Oca M, Thirion-Romero I, et al. Trajectories of spirometric patterns, obstructive and PRISm, in a population-based cohort in Latin America[J]. Int J Chron Obstruct Pulmon Dis, 2023:1277-1285. DOI: 10.2147/COPD.S406208.
[11]	Li D, Ruan Z S, Xie S, et al. The relationship between preserved ratio impaired spirometry and mortality in the myocardial infarction survivors: a population-based cohort study[J]. BMC Cardiovasc Disord, 2023, 23(1): 331. DOI: 10.1186/s12872-023-03352-2.
[12]	Marott J L, Ingebrigtsen T S, Çolak Y, et al. Trajectory of preserved ratio impaired spirometry: natural history and long-term prognosis[J]. Am J Respir Crit Care Med, 2021, 204(8): 910-920. DOI: 10.1164/rccm.202102-0517oc.
[13]	Wan E S, Fortis S, Regan E A, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study[J]. Am J Respir Crit Care Med, 2018, 198(11): 1397-1405. DOI: 10.1164/rccm.201804-0663oc.
[14]	Phillips D B, James M D, Vincent S G, et al. Physiological characterization of preserved ratio impaired spirometry in the CanCOLD study: implications for exertional dyspnea and exercise intolerance[J]. Am J Respir Crit Care Med, 2024, 209(11): 1314-1327. DOI: 10.1164/rccm.202307-1184OC.
[15]	Lei J P, Huang K, Wu S N, et al. Heterogeneities and impact profiles of early chronic obstructive pulmonary disease status: findings from the China Pulmonary Health Study[J]. Lancet Reg Health West Pac, 2024, 45: 101021. DOI: 10.1016/j.lanwpc.2024.101021.
[16]	Zhao N N, Wu F, Peng J Q, et al. Preserved ratio impaired spirometry is associated with small airway dysfunction and reduced total lung capacity[J]. Respir Res, 2022, 23(1): 298. DOI: 10.1186/s12931-022-02216-1.
[17]	Warburton D, Gauldie J, Bellusci S, et al. Lung development and susceptibility to chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2006, 3(8): 668-672. DOI: 10.1513/pats.200605-122SF.
[18]	Cortés-Ibáñez F O, Johnson T, Mascalchi M, et al. Serum-based biomarkers associated with lung cancer risk and cause-specific mortality in the German randomized Lung Cancer Screening Intervention (LUSI) trial[J]. Transl Lung Cancer Res, 2023, 12(12): 2460-2475. DOI: 10.21037/tlcr-23-548.
[19]	Robertson N M, Centner C S, Tejwani V, et al. Preserved ratio impaired spirometry prevalence, risk factors, and outcomes a systematic review and meta-analysis[J]. CHEST, 2025, 167(6): 1591-1614. DOI: 10.1016/j.chest.2024.12.025.
[20]	Kanetake R, Takamatsu K, Park K, et al. Prevalence and risk factors for COPD in subjects with preserved ratio impaired spirometry[J]. BMJ Open Respir Res, 2022, 9(1): e001298. DOI: 10.1136/bmjresp-2022-001298.
[21]	Wijnant S R A, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study[J]. Eur Respir J, 2020, 55(1): 1901217. DOI: 10.1183/13993003.01217-2019.
[22]	Talaminos Barroso A, Márquez Martín E, Roa Romero L M, et al. Factors affecting lung function: a review of the literature[J]. Arch Bronconeumol, 2018, 54(6): 327-332. DOI: 10.1016/j.arbres.2018.01.030.
[23]	Mafort T T, Rufino R, Costa C H, et al. Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function[J]. Multidiscip Respir Med, 2016, 11: 28. DOI: 10.1186/s40248-016-0066-z.
[24]	Carey I M, Cook D G, Strachan D P. The effects of adiposity and weight change on forced expiratory volume decline in a longitudinal study of adults[J]. Int J Obes Relat Metab Disord, 1999, 23(9): 979-985. DOI: 10.1038/sj.ijo.0801029.
[25]	Arismendi E, Bantulà M, Perpiñá M, et al. Effects of obesity and asthma on lung function and airway dysanapsis in adults and children[J]. J Clin Med, 2020, 9(11): 3762. DOI: 10.3390/jcm9113762.
[26]	Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity[J]. Am J Respir Crit Care Med, 2009, 179(6): 509-516. DOI: 10.1164/rccm.200807-1195oc.
[27]	Klein O L, Krishnan J A, Glick S, et al. Systematic review of the association between lung function and type 2 diabetes mellitus[J]. Diabet Med, 2010, 27(9): 977-987. DOI: 10.1111/j.1464-5491.2010.03073.x.
[28]	Schrijver J, Lenferink A, Brusse-Keizer M, et al. Self-management interventions for people with chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2023, 2023(3): CD002990. DOI: 10.1002/14651858.cd002990.pub4.
[29]	Yeh F, Dixon A E, Marion S, et al. Obesity in adults is associated with reduced lung function in metabolic syndrome and diabetes: the Strong Heart Study[J]. Diabetes Care, 2011, 34(10): 2306-2313. DOI: 10.2337/dc11-0682.
[30]	Zhu J H, Zhao H L, Chen D W, et al. Genetic correlation and bidirectional causal association between type 2 diabetes and pulmonary function[J]. Front Endocrinol, 2021, 12: 777487. DOI: 10.3389/fendo.2021.777487.
[31]	Alison J A, Mckeough Z J, Johnston K, et al. Australian and New Zealand pulmonary rehabilitation guidelines[J]. Respirology, 2017, 22(4): 800-819. DOI: 10.1111/resp.13025.
[32]	Hsia C C W, Raskin P. Lung function changes related to diabetes mellitus[J]. Diabetes Technol Ther, 2007, 9(s1): S-73-S-82. DOI: 10.1089/dia.2007.0227.
[33]	Liu L, Feng Q, Wang Y, et al. Interaction of polycyclic aromatic hydrocarbon exposure and high-fasting plasma glucose on lung function decline in coke oven workers: a cross-lagged panel analysis[J]. Environ Toxicol Pharmacol, 2022, 90: 103811. DOI: 10.1016/j.etap.2022.103811.
[34]	Kotlyarov S, Bulgakov A. Lipid metabolism disorders in the comorbid course of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease[J]. Cells, 2021, 10(11): 2978. DOI: 10.3390/cells10112978.
[35]	Hoffmann C, Gerber P A, Cavelti-Weder C, et al. Liver, nafld and COVID-19[J]. Horm Metab Res, 2022, 54(8): 522-531. DOI: 10.1055/a-1834-9008.
[36]	Shin J, Toyoda S, Nishitani S, et al. SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1[J]. Metabolism, 2022, 133: 155236. DOI: 10.1016/j.metabol.2022.155236.
[37]	Margretardottir O B, Thorleifsson S J, Gudmundsson G, et al. Hypertension, systemic inflammation and body weight in relation to lung function impairment—an epidemiological study[J]. COPD J Chronic Obstr Pulm Dis, 2009, 6(4): 250-255. DOI: 10.1080/15412550903049157.
[38]	Engström G, Hedblad B, Valind S, et al. Increased incidence of myocardial infarction and stroke in hypertensive men with reduced lung function[J]. J Hypertens, 2001, 19(2): 295-301. DOI: 10.1097/00004872-200102000-00017.
[39]	Im Y, Park H Y, Lee J Y, et al. Impact of preserved ratio impaired spirometry on coronary artery calcium score progression: a longitudinal cohort study[J]. ERJ Open Res, 2024, 10(1): 819-2023. DOI: 10.1183/23120541.00819-2023.
[40]	Enright P L, Kronmal R A, Smith V E, et al. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study[J]. Chest, 1995, 107(1): 28-35. DOI: 10.1378/chest.107.1.28.
[41]	Jin Z, Wang G F. Some future directions for genome-wide association studies of preserved ratio impaired spirometry[J]. Eur Respir J, 2024, 63(3): 2400142. DOI: 10.1183/13993003.00142-2024.
[42]	Xiao T, Wijnant S R A, Van Der Velpen I, et al. Lung function impairment in relation to cognition and vascular brain lesions: the Rotterdam Study[J]. J Neurol, 2022, 269(8): 4141-4153. DOI: 10.1007/s00415-022-11027-9.
[43]	Wu Y, Vollmer W M, Buist A S, et al. Relationship between lung function and blood pressure in Chinese men and women of Beijing and Guangzhou[J]. Int J Epidemiol, 1998, 27(1): 49-56. DOI: 10.1093/ije/27.1.49.
[44]	He D, Sun Y L, Gao M S, et al. Different risks of mortality and longitudinal transition trajectories in new potential subtypes of the preserved ratio impaired spirometry: evidence from the English longitudinal study of aging[J]. Front Med, 2021, 8: 755855. DOI: 10.3389/fmed.2021.755855.
[45]	Ogata H, Sha K C, Kotetsu Y, et al. The prognostic performance of lung diffusing capacity in preserved ratio impaired spirometry: an observational cohort study[J]. Int J Chronic Obstr Pulm Dis, 2022, 17: 2791-2799. DOI: 10.2147/COPD.S384074.
[46]	Miura S, Iwamoto H, Omori K, et al. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality[J]. Sci Rep, 2023, 13(1): 2988. DOI: 10.1038/s41598-023-29922-0.
[47]	Lu J J, Ge H Y, Qi L, et al. Subtyping preserved ratio impaired spirometry (PRISm) by using quantitative HRCT imaging characteristics[J]. Respir Res, 2022, 23(1): 309. DOI: 10.1186/s12931-022-02113-7.
[48]	Lynch D A, Austin J H M, Hogg J C, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the fleischner society[J]. Radiology, 2015, 277(1): 192-205. DOI: 10.1148/radiol.2015141579.
[49]	Sun C Y, Lee W J, Shen H C, et al. Activin A as a potential biomarker for preserved ratio impaired spirometry (PRISm) and clinical outcomes in community-dwelling adults[J]. Arch Gerontol Geriatr, 2024, 126: 105539. DOI: 10.1016/j.archger.2024.105539.
[50]	Yoon S M, Jin K N, Lee H J, et al. Acute exacerbation and longitudinal lung function change of preserved ratio impaired spirometry[J]. Int J Chronic Obstr Pulm Dis, 2024, 19: 519-529. DOI: 10.2147/copd.s445369.
[51]	Choi Y J, Lee M J, Byun M K, et al. Roles of inflammatory biomarkers in exhaled breath condensates in respiratory clinical fields[J]. Tuberc Respir Dis, 2024, 87(1): 65-79. DOI: 10.4046/trd.2023.0028.
[52]	Higbee D H, Lirio A, Hamilton F, et al. Genome-wide association study of preserved ratio impaired spirometry (PRISm)[J]. Eur Respir J, 2024, 63(1): 2300337. DOI: 10.1183/13993003.00337-2023.
[53]	2025 Gold Report[EB/OL].[2025-06-04].
[54]	Shiraishi Y, Shimada T, Tanabe N, et al. The prevalence and physiological impacts of centrilobular and paraseptal emphysema on computed tomography in smokers with preserved ratio impaired spirometry[J]. ERJ Open Res, 2022, 8(2): 63-2022. DOI: 10.1183/23120541.00063-2022.
[55]	Williams D M. Clinical pharmacology of corticosteroids[J]. Respir Care, 2018, 63(6): 655-670. DOI: 10.4187/respcare.06314.
[56]	Fortis S, Corazalla E O, Jacobs D R Jr, et al. Persistent empiric COPD diagnosis and treatment after pulmonary function test showed no obstruction[J]. Respir Care, 2016, 61(9): 1192-1200. DOI: 10.4187/respcare.04647.

1秒率正常的肺功能受损人群现状、挑战及应对策略

The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 56

相关文章 15

编辑推荐

Metrics

留言

[1]	贺洋, 杨荣, 沈灿, 易珊烨, 刘力滴, 赵茜, 万智, 廖晓阳. 衰弱轨迹及其影响因素研究进展[J]. 中国全科医学, 2026, 29(30): 4372-4378.
[2]	赵佩珍, 赵振东, 许海珠. 海南省新生儿多种遗传代谢病筛查的探索性研究[J]. 中国全科医学, 2026, 29(30): 4438-4444.
[3]	李喜玲, 张帆, 杨欣月, 杨姮. "零食式锻炼"在慢性病管理中应用的范围综述[J]. 中国全科医学, 2026, 29(30): 4472-4479.
[4]	陈毓婧, 王岩, 李光, 董本超, 杨培川, 马剑雄. 数字技术在亚洲地区老年人肌少症干预中应用的范围综述[J]. 中国全科医学, 2026, 29(29): 4200-4210.
[5]	解霄芸, 刘晨曦, 柳羽姝, 周艺涵. 中国基层医疗卫生机构人工智能研究实践及潜在数据贫困问题：一项范围综述[J]. 中国全科医学, 2026, 29(28): 4067-4077.
[6]	冯雅晨, 刘乐伟, 薛金月, 孙先林, 刘寰忠. 可穿戴技术在精神障碍诊疗中的研究进展[J]. 中国全科医学, 2026, 29(27): 4016-4025.
[7]	刘雅慧, 徐雅楠, 袁玲, 武丽桂, 周玉洁, 康玉彪. 基于优先级决策的安宁疗护患者分诊研究范围综述[J]. 中国全科医学, 2026, 29(24): 3538-3544.
[8]	祁晶, 蔡青, 张婉婷, 顾岩. 基于微信小程序的远程肺康复对稳定期慢性阻塞性肺疾病患者多维疗效及依从性研究[J]. 中国全科医学, 2026, 29(24): 3476-3485.
[9]	王睿, 罗说明, 杨靓, 王鹏, 赵洋, 王淇, 周智广. 中国老年人糖尿病患病率：一项系统综述和Meta分析[J]. 中国全科医学, 2026, 29(24): 3500-3508.
[10]	吴礼云, 孙华婧, 顾艺卿, 梅紫琦, 金胜姬, 张素菊, 诸赟, 张瑶, 李琴, 刘小苗, 王庆, 柏亚妹, 徐桂华. 数智化技术用于急性心肌梗死心电监测的范围综述[J]. 中国全科医学, 2026, 29(24): 3545-3552.
[11]	南京大学医学院附属鼓楼医院, 中国康复科学所, 中国康复研究中心, 江苏省整合医学研究会整合营养管理专业委员会, 中国康复医学会康复工程与产业促进专业委员会, 广东省康复医学发展研究会再生修复与抗衰老分会. 青少年特发性脊柱侧凸营养康复管理专家共识[J]. 中国全科医学, 2026, 29(24): 3393-3408.
[12]	吴尔媚, 孙大娟, 邓华亮. 微小RNA在溃疡性结肠炎中的作用及中药干预研究进展[J]. 中国全科医学, 2026, 29(23): 3371-3378.
[13]	王龙雨, 李亚, 马倩, 贾沛霖, 张海龙. 肺一氧化碳弥散量在慢性阻塞性肺疾病中的临床应用研究进展[J]. 中国全科医学, 2026, 29(23): 3379-3384.
[14]	阮何静, 赵文, 李龙灿, 赵久法, 李冬冬. 帕金蛋白在代谢相关脂肪性肝病中的潜在非经典功能及治疗展望[J]. 中国全科医学, 2026, 29(23): 3268-3274.
[15]	李夏夏, 潘一鸣, 刘盼, 宋雨, 李碧汐, 张亚欣, 张婉淑, 李静, 马丽娜. 世界卫生组织老年整合照护筛查工具诊断内在能力下降的灵敏度和特异度分析研究[J]. 中国全科医学, 2026, 29(22): 3199-3205.